Tag Archives: MDT

Top 5 Medical Stocks For 2018

The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.

Some of the biggest gainers among Manufacturing stocks include:

Amicus Therapeutics (FOLD): FOLD stock is up 10.15% today. Aquinox Pharmaceutic (AQXP): AQXP stock is up 9.93% today. Newlink Genetics Cor (NLNK): NLNK stock is up 9.79% today. Achillion Pharmaceut (ACHN): ACHN stock is up 9.77% today. Sgoco Group Ltd (SGOC): SGOC stock is up 9.57% today. Avexis Inc Cmn Stk (AVXS): AVXS stock is up 9.47% today. Aduro Biotech Cmn (ADRO): ADRO stock is up 9.45% today. Arca Biopharma Inc (ABIO): ABIO stock is up 9.26% today. Biocryst Pharma Inc (BCRX): BCRX stock is up 9.22% today. Spark Therap Cmn (ONCE): ONCE stock is up 9.19% today.

Some of the biggest losers among Manufacturing stocks include:

Xplore Tech Corp De (XPLR): XPLR stock is down 4.13% today. Tantech Holdings Cmn (TANH): TANH stock is down 4.02% today. Azurrx Biopharma Inc (AZRX): AZRX stock is down 3.76% today. Aethlon Medical Cmn (AEMD): AEMD stock is down 3.64% today. Kornit Digital Ord (KRNT): KRNT stock is down 3.53% today. Tesco Corp (TESO): TESO stock is down 3.53% today. Ikonics Corp (IKNX): IKNX stock is down 3.52% today. Nymox Pharm Corp (NYMX): NYMX stock is down 3.5% today. Albireo Pharma Inc (ALBO): ALBO stock is down 3.13% today. Nexvet Biopharma Ord (NVET): NVET stock is down 2.78% today.

For more information on the best stocks to buy right now, check out the latest commentary on InvestorPlace.com.

Top 5 Medical Stocks For 2018: EP Energy Corporation(EPE)

Advisors’ Opinion:

  • [By Paul Ausick]

    EP Energy Corp. (NYSE: EPE) posted a new 52-week low of $1.85 Tuesday, down nearly 22% after closing at $2.37 on Monday. The 52-week high is $7.49. Volume was about 3.2 million, around 5 times the daily average of around 600,000. The oil and gas exploration and production firm has launched an exchange program extending the maturity date to 2024 on $1.2 billion in 9.375% notes due in 2020.

  • [By Andrew Efimoff]

    WTI crude oil plunged 3.11 percent on Friday to $48.99 a barrel. Below are the biggest energy losers for the day:

    California Resources Corporation (NYSE: CRC): -19.22%
    Dynamic Materials (NASDAQ: BOOM): -12.39%
    Clayton Williams Energy (NYSE: CWEI): -11.45%
    Dynergy (NYSE: DYN): -11.91%
    EP Energy Corporation (NYSE: EPE): -11.20%
    Mexco Energy (NYSE: MXC) -10.90%
    Whiting Petroleum (NYSE: WLL) -10.79%
    Southwestern Energy Company (NYSE: SWN) -10.79%
    SM Energy Company (NYSE: SM) -10.38%
    Real Goods Solar (NASDAQ: RGSE) -10.34%

    Posted-In: Commodities After-Hours Center Markets Movers

Top 5 Medical Stocks For 2018: Caesars Entertainment Corporation(CZR)

Advisors’ Opinion:

  • [By Michael E. Lewitt]

    Back in April, I recommendedCaesars Entertainment Corp.(Nasdaq: CZR) as a buy – but warned you that this was a play that might take some time to mature.

  • [By Travis Hoium]

    Wynn Resorts (NASDAQ:WYNN) and Caesars Entertainment (NASDAQ:CZR) are two of the most well known gaming companies in the world. But they’re very different companies with very different futures ahead.

  • [By AlphaStreetResearch]

    Caesars Entertainment Corporation (CZR) is a highly overvalued gaming, hotel, and entertainment company with deteriorating fundamentals on all levels in a highly competitive environment. The company’s stock has seen a massive run to the upside on the coattails of other casino and entertainment companies in the space. A considerable catalyst for the push higher in these stocks is the good news coming out of Macau, but this is an area where Caesars has absolutely no exposure and will be locked out of for the foreseeable future after failing to take appropriate licensing measures. Below is our introduction into the business model, its weaknesses, and the new selling or shorting opportunity that exists for CZR after the recent appreciation in share price. Investors will soon realize that there is little upside value in this company and that there are much better opportunities in this space. The company is now amidst a major struggle from a debt standpoint with major deadlines approaching over the next year and a half. The company is in no position to thrive going forward unless major steps are taken to overhaul the company’s capital structure. Caesars Entertainment has a market cap of $3.19 Billion after the stock has moved up over 225% year to date and reports its next quarter on October 31, 2013. With this in mind, we value CZR at $21.00 by year-end of 2013 and $14.00 by August 1, 2014, a decrease of 40% from current levels. We will later highlight:

Top 5 Medical Stocks For 2018: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By George Budwell]

    Keeping this theme in mind, I think the Dividend Aristocrats AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ), and Medtronic plc (NYSE:MDT) are three outstanding stocks to steady any portfolio during these uncertain times. Here’s why.

  • [By Matthew Briar]

    What do you get when you combine a medical device company like Medtronic plc (NYSE:MDT) and a mobile communication device like the iPhone from Apple Inc. (NASDAQ:AAPL)? You get a CardioComm Solutions Inc. (OTCMKTS:EKGGF, CVE:EKG), which can turn your smartphone into a high-powered, high-functioning heart-monitoring piece of hardware as potent as anything you’d have access to in the hospital.

    Yes, there’s a market for the melding of what Apple and Medtronic — and several other players — do. The healthcare wearable market was worth $5.1 billion in 2015, and now that such technologies are being accepted, its revenues could reach $19 billion by 2020. Meanwhile, the heart-monitoring space happens to be a market worth more than $20 billion per year, and some say it will be worth $26.7 billion by 2020. CardioComm Solutions is nestled nicely between the two of them.

    CardioComm Solutions is the name behind a brand of wellness products sold under the HeartCheck monikor. Those devices are small, handheld portable ECG (electrocardiogram) readers that put the power of a doctor’s or hospital’s heart-monitoring hardware in the hands of individuals who can use them just as effectively.

    Its flagship products are the HeartCheck ECG Pen, for consumers (available without a prescription), and the HeartCheck ECG monitoring device (available only by prescription) that’s a higher-level technology. More are on the way too. The ECG ‘Card’ is a credit-card sized device that syncs up with — and is powered by — a smartphone in close proximity. Also on the way is the HeartCheck band, which is worn on the wrist. It does a lot that the Fitbit bands do, with the added benefit of being able to produce clinical-grade ECG readouts viewable not just by the user, but by a doctor, clinic, or call center if that user chooses to deliver them remotely using the company’s platform.

    Bolstering the value proposition is the fact that all of its wares are — or will be

  • [By Ben Levisohn]

    Medtronic (MDT) has risen 1.9% to $81.75 on reports that Cardinal Health (CAH) will buy its medical supplies business.

    Jazz Pharmaceuticals (JAZZ) has jumped 6.3% to $149.45 after settling a patent dispute.

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Todd Campbell]

    At Medtronic (NYSE:MDT), one of the country’s largest medical-device companies, these sensors are even attached to an insulin pump patients wear that canautomatically administer insulin as it’s needed.

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

Top 5 Medical Stocks For 2018: Immersion Corporation(IMMR)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Movers newsletter suggested shorting small cap technology stock Immersion Corporation (NASDAQ: IMMR):

    We love how well developed the selling of Immersion shares has been. Rather than a sharp, v-shaped reversal — which may or may not follow through — we’ve seen a bowl-shaped transition from an uptrend to a downtrend. This ups the odds of downside follow-through, as there’s been no price “shock” to invite a sudden wave of buying.

  • [By Lisa Levin]

    Immersion Corporation (NASDAQ: IMMR) shares were also up, gaining 22 percent to $7.29. Immersion disclosed that Vic Viegas has agreed to resign as CEO and as a director. The company named Carl Schlachte as Interim CEO.

  • [By Lisa Levin]

    Immersion Corporation (NASDAQ: IMMR) shares were also up, gaining 20 percent to $7.18. Immersion disclosed that Vic Viegas has agreed to resign as CEO and as a director. The company named Carl Schlachte as Interim CEO.

Top 5 Medical Stocks For 2018: EV Energy Partners, L.P.(EVEP)

Advisors’ Opinion:

  • [By William Romov]

    Before we show you our pick, here are the top 10 penny stocks to watch this week

    Penny Stock Current Share Price Nov. 27-Dec. 1 Gain (as of Dec. 1)
    Pyxis Tankers Inc. (Nasdaq: PXS) $4.10 122.83%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.28 68.42%
    Cerecor Inc. (Nasdaq: CERC) $1.74 47.46%
    Proteostasis Therapeutics Inc. (Nasdaq: PTI) $2.52 37.71%
    UT Starcom Holdings Corp. (Nasdaq: UTSI) $5.20 37.20%
    WMIH Corp. (Nasdaq: WMIH) $0.96 33.46%
    PhaseRx Inc. (Nasdaq: PZRX) $0.90 30.29%
    Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $2.04 29.94%
    EV Energy Partners LP (Nasdaq: EVEP) $0.86 27.76%
    Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) $4.40 25.71%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, its completely free

  • [By Money Morning Staff Reports]

    But before we show you our pick, here are the top 10 penny stocks to watch this week…

    Penny Stocks Current Share Price (as of Jan. 5) Jan. 2-5 Gain (as of Jan. 5)
    My Size Inc. (Nasdaq: MYSZ) $1.66 152.28%
    Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.47 89.52%
    DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) $1.675 58.02%
    CAS Medical Systems Inc. (Nasdaq: CASM) $1.09 55.71%
    China HGS Real Estate Inc. (Nasdaq: HGSH) $1.83 47.58%
    Aethlon Medical Inc. (Nasdaq: AEMD) $1.56 43.12%
    Midatech Pharma Plc. (Nasdaq: MTP) $1.23 43.01%
    Comstock Holding Cos. Inc. (Nasdaq: CHCI) $1.87 36.5%
    Cenveo Inc. (Nasdaq: CVO) $1.20 31.82%
    EV Energy Partners LP (Nasdaq: EVEP) $0.6844 31.62%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

Hot Undervalued Stocks For 2018

Talk about a Barron’s bounce!Range Resources (RRC) has soared to the top of the S&P 500 today after Barron’s touted it in the pages of the magazine this weekend.

Agence France-Presse/Getty Images

Range Resources gained 4.1% to $28.47, while the S&P 500 slipped 0.3% to2,375.31.

Barron’s Andrew Bary called Range Resources “an unappreciated energy play.” He explains why:

With major market indexes at record highs, natural-gas stocks are among the few depressed industry groups. Blame a warm winter and weakening gas prices.

Range Resources (ticker: RRC), a leading U.S. gas producer, looks undervalued. Its shares, at $27, are down 20% this year and are much below their 52-week high of $47, set last June. Range drilled the first well in the now-prolific Marcellus region of Pennsylvania more than a decade ago and amassed one of its largest land positions there610,000 acres. Its $4.2 billion purchase of Memorial Resource Development last September gave it access to what the company views as a prolific and underappreciated gas region: northern Louisiana

Hot Undervalued Stocks For 2018: Iteris, Inc.(ITI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

Hot Undervalued Stocks For 2018: Tandy Leather Factory, Inc.(TLF)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Armour Residential REIT Inc. (NYSE: ARR), Ducommun Inc. (NYSE: DCO), PJT Partners Inc. (NYSE; PJT), Sonic Automotive Inc. (NYSE: SAH)and Tandy Leather Factory Inc. (NASDAQ: TLF).

Hot Undervalued Stocks For 2018: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By Nelson Hem]

    Lawrence C. Strauss’s “Medtronic: Healthy and Getting Healthier” points out that some investors are skeptical about the prospects for this Dublin-based medical device maker. But are those investors underestimating the strength of Medtronic PLC (NYSE: MDT)? Find out why Barron’s believes the company’s shares could climb up to 15 percent over the next 12 months.

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Paul Ausick]

    Medtronic plc (NYSE: MDT) dropped about 2.6% Tuesday to post a new 52-week low of $69.35 after closing Friday at $71.23. The 52-week high is $89.27. Volume of around 8.6 million was about 20% more than the daily average of around 6.2 million shares traded. The company’s stock was downgraded this morning at Morgan Stanley.

Hot Undervalued Stocks For 2018: Hercules Offshore Inc.(HERO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Hercules Offshore, Inc. (NASDAQ: HERO) shares dropped 46 percent to $1.05 as the company reported that it has entered into a restructuring support agreement with lenders.

  • [By Monica Gerson]

    Hercules Offshore, Inc. (NASDAQ: HERO) is estimated to post a quarterly loss at $1.79 per share on revenue of $68.65 million.

    You On Demand Holdings, Inc. (NASDAQ: YOD) is expected to report its quarterly earnings.

Hot Undervalued Stocks For 2018: Female Health Company (The)(FHCO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Female Health Co (NASDAQ: FHCO) were down 15 percent to $1.46 as the company reported that it has entered into a merger agreement with Aspen Park Pharma.

Hot Heal Care Stocks To Invest In 2018

Many holders of The Trade Desk (TTD) are disappointed by the recent drop after Q3 earnings. The stock sold off on what was a strong earnings report and what was seen as “soft” guidance. This is likely because they didn’t much increase their full-year forecast and Q4 guidance over what they gave during the Q2 report. The market has been pricing in very high growth expectations and as growth slows the price will become more powered by earnings. Since the fall the stock has stabilized and in my opinion remains a very strong buy. The CEO Jeff Green is very much a visionary in the advertising industry, trying to push the boundaries of analytical data-driven advertising. Over the next several years we will continue to see a big push toward programmatic advertising as well as native ads. These changes often happen more abruptly than you would expect, as services like Netflix (NFLX) and Hulu speed up adoption. If you have a good risk tolerance TTD will continue to be volatile but provide exceptional growth with great management. Lets take a peak at the Q3 quarter.

Hot Heal Care Stocks To Invest In 2018: Callon Petroleum Company(CPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

Hot Heal Care Stocks To Invest In 2018: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.

  • [By SEEKINGALPHA.COM]

    Online Direct Sales – Once only consumer electronics and mobile handsets, the products it offers has grown to include 15 different categories, including home appliances and a wide array of general merchandise.

    In April, JD.com became a certified member of the American Apparel & Footwear Association (AAFA), the trusted public policy and political voice of the apparel and footwear industry, a first for a Chinese e-commerce company. In the first quarter of 2017, Avene, the leading demo-cosmetic brand for sensitive skin in European pharmacies, and three brands under Georgio Armani launched flagship stores on JD.com’s direct sales platform. JD Worldwide, a cross-border e-commerce platform set up in April 2015 to provide access to international brands (including those not available in China), has retail contracts with international brands such as Wal-Mart (NYSE:WMT), Phillips, Barcelona FC, and GNC (NYSE:GNC). Recently, it’s partnered with ASDA, a leading UK retailer under the Wal-Mart umbrella, as well as Bayer (OTCPK:BAYZF) and Cetaphil. As of March 2017, it operates 263 warehouses covering a gross floor area of 5.8 million square meters. GMV from the online direct sales business was RMB107.9 billion in the first quarter of 2017, up 42% from the first quarter of 2016. Net revenues from online direct sales increased by 40% in the first quarter of 2017 as compared to the first quarter of 2016. Fulfilled orders in the first quarter of 2017 were 477.1 million, an increase of 39% from 342.1 million in the same period in 2016. Fulfilled orders placed through mobile accounted for approximately 81% of total orders fulfilled in the first quarter of 2017, an increase of 56% compared to the same period in 2016.

    Online Marketplace – Third-party sellers offer products to customers and pay a commission to JD.com. They provide transaction processing and billing services on all orders on the online marketplace and leverage their own nationwide fulfillment infrastructu

  • [By SEEKINGALPHA.COM]

    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.

    Click to enlarge

  • [By SEEKINGALPHA.COM]

    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

Hot Heal Care Stocks To Invest In 2018: PetMed Express, Inc.(PETS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Peter Graham]

    A long term performance chart shows Blue Buffalo Pet Products roughly back up to its IPO close for retail investors while fresh pet food peer Freshpet Inc (NASDAQ: FRPT) isstill below IPO levels and pet stocksCentral Garden & Pet Co (NASDAQ: CENT) andPetmed Express (NASDAQ: PETS) have been much stronger performers in the pet sector after PetSmart (NASDAQ: PETM) was acquired by a private equity group:

  • [By Lisa Levin]

    Monday afternoon, the non-cyclical consumer goods & services shares surged 0.22 percent. Meanwhile, top gainers in the sector included Petmed Express Inc (NASDAQ: PETS), up 20 percent, and Kroger Co (NYSE: KR), up 3 percent.

  • [By Peter Graham]

    A long term performance chart shows Blue Buffalo Pet Products now roughly back up to its IPO close for retail investors while fresh pet food peer Freshpet Inc (NASDAQ: FRPT) is well below IPO levels and pet stocksCentral Garden & Pet Co (NASDAQ: CENT) andPetmed Express (NASDAQ: PETS) have been the best performers in the pet sector after PetSmart (NASDAQ: PETM) was acquired by a private equity group:

  • [By Peter Graham]

    Small cap pet stockPetmed Express Inc (NASDAQ: PETS) reportedQ2 earnings before the market opened this morning with shares soaring this morning as earnings were well beyond expectations. Net sales increased 10% to $66.7 million as new order sales increased 9% to $11.6 million while the Company’s online sales for the quarter ended September 30, 2017 were approximately 84% of all sales compared to 82% for the same quarter the prior year (with online sales increasing 12%). Net income was $8.8 million versusnet income of $4.9 million. The CEO commented:

Hot Heal Care Stocks To Invest In 2018: One Horizon Group, Inc.(OHGI)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

Hot Heal Care Stocks To Invest In 2018: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Medtronic (MDT) has risen 1.9% to $81.75 on reports that Cardinal Health (CAH) will buy its medical supplies business.

    Jazz Pharmaceuticals (JAZZ) has jumped 6.3% to $149.45 after settling a patent dispute.

  • [By Ben Levisohn]

    Cardinal Health (CAH) tumbled to the bottom of the S&P 500 today after agreeing to buy Medtronic’s (MDT) medical supplies business for $6.1 billion and offering disappointing guidance.

  • [By ]

    Medical device makers will also be in the price-control crosshairs. If the government can mandate drug prices, the same can be expected for pacemakers, artificial joints and other devices. Companies such as Medtronic (NYSE: MDT) and previously mentioned pharma giant Johnson & Johnson will find themselves adjusting to a new paradigm.

Hot Heal Care Stocks To Invest In 2018: Cray Inc(CRAY)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tuesday afternoon, the technology sector proved to be a source of strength for the market. Leading the sector was strength from Cray Inc. (NASDAQ: CRAY) and Mellanox Technologies, Ltd. (NASDAQ: MLNX).

  • [By Jim Robertson]

    Cray Inc. (CRAY) has been one of those feast or famine small caps that have either made traders and investors a lot of money in recent years – or simply frustrated those who’ve held it for quite some time. However, at this point we think CRAY offers an attractive risk/reward opportunity on a long-term basis for investors interested in exposure to big data analytics and specifically super-computing – a growing need for large enterprise and institutions all over the world

  • [By Peter Graham]

    The Q4 2016 earnings report for small capsupercomputer stock Cray Inc (NASDAQ: CRAY) is scheduled forafter the market closes onWednesday (February 8th). Back in 2012, Cray Inc was inour SmallCap Network Elite Opportunity (SCN EO) portfolioasa potentially goodlow risk longer-term play as shares were trading at the $12 level and eventually hit $40+ per share before coming back down to earth last year.

hot stocks

What was Gawker? A trailblazing, piercer of pretense? A snarky, vestigial leftover of the early bloggy web? A company that early on understood the relationship between reader enthusiasm and selling stuff?

Probably all three. It’s the last one though — Founder Nick Denton’s embrace of selling goods — that may be one of its greatest legacies.

Last August, Univision surprised the publishing community with its $135 million purchase of Gawker’s assets out of its legal woe-driven bankruptcy. In the eight months since, that purchase has led to a renewed Univision digital strategy, and much of that drive has been propelled by commerce, initiated by Denton and now set to widely multiply, as Univision’s main Spanish-language site plans to move more deeply into the commerce game itself.

hot stocks: Realogy Holdings Corp.(RLGY)

Advisors’ Opinion:

  • [By Monica Wolfe]

    Realogy Holdings (RLGY)

    Paulsons third largest holding goes to Realogy Holdings. The guru holds on to 12,957,700 shares, representing 4.4% of his total portfolio and 8.87% of the companys shares outstanding.

  • [By Chad Tracy]

    Investments in Claire's retail stores, Realogy Holdings (NYSE: RLGY), and Harrah's Entertainment all came under pressure as the global credit crisis hit. Apollo was forced to shut off cash interest payments to investors and to issue more debt.  

  • [By Lisa Abramowicz]

    Drugstore chain Rite Aid Corp. (RAD) and residential property firm Realogy Corp. (RLGY) are two of the 283 junk-rated borrowers identified in March 2009 by Moodys Investors Service as being at the highest risk of default that have since sold bonds.

hot stocks: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Medtronic (MDT) has risen 1.9% to $81.75 on reports that Cardinal Health (CAH) will buy its medical supplies business.

    Jazz Pharmaceuticals (JAZZ) has jumped 6.3% to $149.45 after settling a patent dispute.

  • [By George Budwell]

    Keeping this theme in mind, I think the Dividend Aristocrats AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ), and Medtronic plc (NYSE:MDT) are three outstanding stocks to steady any portfolio during these uncertain times. Here’s why.

  • [By ]

    Medical device makers will also be in the price-control crosshairs. If the government can mandate drug prices, the same can be expected for pacemakers, artificial joints and other devices. Companies such as Medtronic (NYSE: MDT) and previously mentioned pharma giant Johnson & Johnson will find themselves adjusting to a new paradigm.

  • [By Ben Levisohn]

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

hot stocks: Dell Technologies Inc. (DVMT)

Advisors’ Opinion:

  • [By Lee Jackson]

    Avery familiar technology face was acquiring shares of Dell Technologies Inc. (NASDAQ: DVMT) last week. The legendary Michael Dell himself was purchasedshares in the newest incarnation of the famed Dell franchise. Heacquired a total of 254,545 shares at a very reduced price of $27.50, which could be option-related. The total for the trade was posted at $7 million.

hot stocks: New York REIT, Inc.(NYRT)

Advisors’ Opinion:

  • [By Paul Ausick]

    New York REIT Inc. (NYSE: NYRT) dropped about 2.9% Wednesday to post a new 52-week low of $8.01after closing Tuesday at $8.25. The 52-week high is $10.15. Volume of around 4.7 million shares traded was more than triple the daily average. The company had no specific news.

  • [By Paul Ausick]

    New York REIT Inc. (NYSE: NYRT) also matched a 52-week low of $3.90 Monday. The stock’s 52-week high is $10.15. Volume of about 1.7 million was about 20% below the daily average. The company had no specific news. The stock is set to close up about 0.3% today.

  • [By Paul Ausick]

    New York REIT Inc. (NYSE: NYRT) dropped about 2% Wednesday to post a new 52-week low of $4.95 after closing at $5.05 on Tuesday. The 52-week high is $10.15. Volume was around 4 million, about 40% above the daily average of around 2.9million. The company had no specific news.

  • [By Paul Ausick]

    New York REIT Inc. (NYSE: NYRT) dropped about 11.8% Thursday to post a new 52-week low of $8.55 after closing at $9.69 on Wednesday. The stock’s 52-week high is $10.15. Volume was nearly 20 times the daily average of around 1.9 million shares. The company, which is in the process of liquidating its assets in New York City, announced quarterly results Wednesday afternoon, including a liquidation value of the portfolio of $9.25 per share.

hot stocks: MicroStrategy Incorporated(MSTR)

Advisors’ Opinion:

  • [By Jim Robertson]

    Small cap Alarm.com Holdings would bethe leading platform for the intelligently connected property. Millions of people depend on Alarm.com Holdings technology to monitor and control their property from anywhere. Centered on security and remote monitoring, the Companys platform addresses a wide range of market needs and enables application-based control for a growing variety of Internet of Things (IoT) devices.Its security, video monitoring, intelligent automation and energy management solutions are available througha network of thousands of professional service providers in North America and around the globe. The Company went public in June 2015 as a spinoff from MicroStrategy Incorporated (NASDAQ: MSTR) with shares selling for $14 during the IPO.

  • [By Chris Neiger]

    MicroStrategy (NASDAQ:MSTR) reported its first-quarter results on April 27, and the company saw its total revenue tick up by 1.3% year over year. Just as with the company’s fourth-quarter results, MicroStrategy’s management said foreign-currency headwinds continued to have a negative impact on the company’s overall sales.

stock market symbols

Related AXON Oppenheimer Presents New Menu Of Top Picks Arena Upgraded, Analyst Sees 44% Upside
Related LEN 25 Stocks Moving In Tuesday's Pre-Market Session Homebuilders Under Pressure After Housing Market Index Hits 8-Month Low

Benzinga Pro provides its subscribers with real-time alerts of potentially market-moving options activity.

Here's a recap of the options alerts from Friday, September 18, 2017. All time stamps are in Eastern Time.

3:43:30 pm: AXON Axovant Oct 20 $40 Calls Above Ask!: 5998 @ $7.22 vs 5220 OI; Ref=$22.77

2:57:30 pm: LEN Lennar Oct 20 $52.5 Calls at the Bid: 1732 @ $0.99 vs 427 OI; Ref=$51.76

2:33:41 pm: MAT Mattel Oct 20 $15 Puts Sweep (2) at the Ask: 7500 @ $0.776 vs 7020 OI; Ref=$14.8

1:59:08 pm: NG NovaGold Oct 20 $5 Puts Sweep (10) at the Bid: 872 @ $0.902 vs 20 OI; Ref=$4.12

1:52:02 pm: BIG Big Lots Oct 20 $47.5 Puts Sweep (29) at the Bid: 1919 @ $0.7 vs 465 OI; Ref=$49.84

stock market symbols: Fiesta Restaurant Group, Inc.(FRGI)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows El Pollo LoCo Holdings stabilizing over thepast two yearswhile potentialpeers like large cap Chipotle Mexican Grill, Inc (NYSE: CMG) andsmall capsFiesta Restaurant Group Inc (NASDAQ: FRGI) and Chuy’s Holdings Inc (NASDAQ: CHUY)have performed better in the past and appear to be in downtrends for the past 1 1/2 years:

  • [By Peter Graham]

    A long term performance chart shows Del Taco Restaurants now outperforming Mexican restaurant stock peers such as mid cap Chipotle Mexican Grill, Inc (NYSE: CMG) and small caps El Pollo LoCo Holdings Inc (NASDAQ: LOCO), Fiesta Restaurant Group Inc (NASDAQ: FRGI) and Chuy’s Holdings Inc (NASDAQ: CHUY) have mostly been drifting lower lately:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

  • [By Peter Graham]

    A long term performance chart shows Chipotle Mexican Grills shares back to breakeven while of the small caps peers, El Pollo LoCo Holdings Inc (NASDAQ: LOCO) has had the worst performance, Fiesta Restaurant Group Inc (NASDAQ: FRGI) is off its 2015s peak and Chuy’s Holdings Inc (NASDAQ: CHUY) has been a mixed performer:

  • [By Lisa Levin]

    Fiesta Restaurant Group Inc (NASDAQ: FRGI) shares dropped 24 percent to $19.83. Fiesta Restaurant posted in-line Q4 earnings, but sales missed estimates. The company also disclosed that it has suspended its sale exploration process and appointed a new CEO. Raymond James downgraded Fiesta Restaurant from Outperform to Market Perform.

stock market symbols: BioPharmX Corporation(BPMX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of BioPharmX Corp (NYSE: BPMX) were down 31 percent to $1.02 after the company announced the pricing of 3.6 million share common stock.

    Puma Biotechnology Inc (NYSE: PBYI) was down, falling around 22 percent to $27.53 after the company issued an update to the timeline for the filing of a new drug application. Puma Biotechnology will submit the NDA for neratinib in mid-2016. According to a press release, the decision was based on the company’s recent meetings with the U.S. Food and Drug Administration.

stock market symbols: Omega Healthcare Investors, Inc.(OHI)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Or, consider Omega Healthcare Investors (OHI). The Maryland-based company invests heavily in hospital properties and health care facilities, with a special emphasis on nursing facilities.

  • [By Paul Ausick]

    Omega Healthcare Investors Inc. (NYSE: OHI) dropped about 2.6% Monday to post a new 52-week low of $26.43 after closing at $27.14 on Friday. The 52-week high is $35.14. Volume was around 5.3 million, more than double the daily average of around 2.3 million. The healthcare REIT had now specific news.

stock market symbols: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By Nelson Hem]

    Lawrence C. Strauss’s “Medtronic: Healthy and Getting Healthier” points out that some investors are skeptical about the prospects for this Dublin-based medical device maker. But are those investors underestimating the strength of Medtronic PLC (NYSE: MDT)? Find out why Barron’s believes the company’s shares could climb up to 15 percent over the next 12 months.

  • [By Todd Campbell]

    At Medtronic (NYSE:MDT), one of the country’s largest medical-device companies, these sensors are even attached to an insulin pump patients wear that canautomatically administer insulin as it’s needed.

  • [By Matthew Briar]

    What do you get when you combine a medical device company like Medtronic plc (NYSE:MDT) and a mobile communication device like the iPhone from Apple Inc. (NASDAQ:AAPL)? You get a CardioComm Solutions Inc. (OTCMKTS:EKGGF, CVE:EKG), which can turn your smartphone into a high-powered, high-functioning heart-monitoring piece of hardware as potent as anything you’d have access to in the hospital.

    Yes, there’s a market for the melding of what Apple and Medtronic — and several other players — do. The healthcare wearable market was worth $5.1 billion in 2015, and now that such technologies are being accepted, its revenues could reach $19 billion by 2020. Meanwhile, the heart-monitoring space happens to be a market worth more than $20 billion per year, and some say it will be worth $26.7 billion by 2020. CardioComm Solutions is nestled nicely between the two of them.

    CardioComm Solutions is the name behind a brand of wellness products sold under the HeartCheck monikor. Those devices are small, handheld portable ECG (electrocardiogram) readers that put the power of a doctor’s or hospital’s heart-monitoring hardware in the hands of individuals who can use them just as effectively.

    Its flagship products are the HeartCheck ECG Pen, for consumers (available without a prescription), and the HeartCheck ECG monitoring device (available only by prescription) that’s a higher-level technology. More are on the way too. The ECG ‘Card’ is a credit-card sized device that syncs up with — and is powered by — a smartphone in close proximity. Also on the way is the HeartCheck band, which is worn on the wrist. It does a lot that the Fitbit bands do, with the added benefit of being able to produce clinical-grade ECG readouts viewable not just by the user, but by a doctor, clinic, or call center if that user chooses to deliver them remotely using the company’s platform.

    Bolstering the value proposition is the fact that all of its wares are — or will be

  • [By Ben Levisohn]

    Cardinal Health (CAH) tumbled to the bottom of the S&P 500 today after agreeing to buy Medtronic’s (MDT) medical supplies business for $6.1 billion and offering disappointing guidance.

  • [By Paul Ausick]

    Medtronic plc (NYSE: MDT) dropped about 2.6% Tuesday to post a new 52-week low of $69.35 after closing Friday at $71.23. The 52-week high is $89.27. Volume of around 8.6 million was about 20% more than the daily average of around 6.2 million shares traded. The company’s stock was downgraded this morning at Morgan Stanley.

stock market symbols: Alliance Data Systems Corporation(ADS)

Advisors’ Opinion:

  • [By Teresa Rivas]

    Alliance Data Systems (ADS) was the worst performer in the S&P 500 Tuesday.

    Getty Images

    ADS shares fell $9.32, or 3.8%, to $238.32, compared to the S&P 500, which fell 3.38 points, or 0.14%, to 2353.78.

    The shares were hurt by a bearish note from Oppenheimer: Analysts Ben Chittenden and Dominick Gabriele initiated coverage of the stock with an Underperform rating and a $185 price target.

    Details from the note:

    Long investors seem generally to believe that the profitability of ADS’s capital-light/data-driven/tech-based businesses (Epsilon/LoyaltyOne) will turn relatively soon and that EPS will be driven by more than just the card business. The logical conclusion is the multiple should be FinTech-based. We think it’s just as easy to make the case that, while ADS had a first-mover advantage on data-driven, SKU-level analytics, competitive advantage is diminishing and the profitability of these businesses will likely take longer to turn (and likely not return to historical levels). Thus, earnings will continue to be driven by the balance sheet-intensive card business (our ’18E EPS is 6% below consensus) and should be valued as such, we think.

    Advanced Micro Devices(AMD) was the worst performer in the S&P 500 yesterday.

     

  • [By Ben Levisohn]

    Alliance Data Systems (ADS) soared to the top of the S&P 500 today after beating the Street’s earnings and revenue expectations.

    Getty Images

    Alliance Data Systemsgained 8.3% to $260.62, while the S&P 500 rose 0.8% to 2,355.84.

    Evercore ISI’s David Togut and team argue that Alliance Data Systems is “checking the right boxes.” They explain:

    ADS’ 1Q/17 earnings reinforced our conviction that net charge offs will stabilize at the end of this year, driving accelerating earnings growth in 2018. Card Services surpassed our revenue and EBITDA forecasts fueled by an 80 basis point increase in gross card yield thanks to rising interest rates. Epsilon’s revenue growth accelerated to 7% from a 1% decline in 4Q/16 driven by double digit growth in Automotive, Agency and digital CRM plus an easy comparison. LoyaltyOne revenue and EBITDA fell below our estimates given soft results from AIR MILES, which is adjusting its value proposition after the Ontario Legislature last December eliminated the expiration date on AIR MILES. Overall, ADS remains on track to generate double-digit adjusted EBITDA and EPS gains in 2017, and in 2018 to accelerate EPS growth to the mid-teens given slowing headwinds from delinquencies plus operating leverage from stabilizing net charge-off rates.

    Alliance Data Systems’ market capitalization rose to $14.6 billion today from $13.5 billion yesterday.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Tuesday was Alliance Data Systems Corp. (NYSE: ADS) which traded down 3.9% at $238.00. The stocks 52-week range is $185.02 to $254.94. Volume was 1.6 million versus the daily average of 577,000 shares.

stock market symbols: Insulet Corporation(PODD)

Advisors’ Opinion:

  • [By Brian Feroldi]

    Shares of Insulet Corporation(NASDAQ:PODD), a medical device company primarily focused on diabetes,rose by as much as 11% in afternoon trading on Friday.

  • [By Peter Graham]

    A long term performance chart shows MannKind Corporation having once been a highflyerwhile the performance of large cap insulin and diabetes stockNovo Nordisk A/S (NYSE: NVO) has fallen off and small cap Insulet Corporation (NASDAQ: PODD) has actually performed better:

  • [By Peter Graham]

    A long term performance chart shows MannKind Corporation peaking in 2014 before falling below the more steady performance of diabetes or insulin stocks like large cap Novo Nordisk A/S (NYSE: NVO) and small cap Insulet Corporation (NASDAQ: PODD):

best stocks to buy today

CEO and President of EWI Inc. of Euronet Worldwide Inc (NASDAQ:EEFT) Michael J Brown sold 60,000 shares of EEFT on 08/01/2017 at an average price of $96.49 a share. The total sale was $5.8 million.

Euronet Worldwide Inc is an electronic payments provider. It offers payment and transaction processing and distribution solutions to financial institutional, retailers, service providers and individual consumers. Euronet Worldwide Inc has a market cap of $5.1 billion; its shares were traded at around $97.26 with a P/E ratio of 31.26 and P/S ratio of 2.61. Euronet Worldwide Inc had annual average EBITDA growth of 18.10% over the past five years.

CEO Recent Trades:

CEO and President of EWI Inc. Michael J Brown sold 60,000 shares of EEFT stock on 08/01/2017 at the average price of $96.49. The price of the stock has increased by 0.8% since.

Directors and Officers Recent Trades:

Exec VP and General Counsel Jeffrey B Newman sold 24,535 shares of EEFT stock on 07/24/2017 at the average price of $92.01. The price of the stock has increased by 5.71% since.Exec VP and General Counsel Jeffrey B Newman sold 3,433 shares of EEFT stock on 07/19/2017 at the average price of $92. The price of the stock has increased by 5.72% since.

For the complete insider trading history of EEFT, click here

best stocks to buy today: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By ]

    Medical device makers will also be in the price-control crosshairs. If the government can mandate drug prices, the same can be expected for pacemakers, artificial joints and other devices. Companies such as Medtronic (NYSE: MDT) and previously mentioned pharma giant Johnson & Johnson will find themselves adjusting to a new paradigm.

  • [By Ben Levisohn]

    Medtronic (MDT) has risen 1.9% to $81.75 on reports that Cardinal Health (CAH) will buy its medical supplies business.

    Jazz Pharmaceuticals (JAZZ) has jumped 6.3% to $149.45 after settling a patent dispute.

  • [By George Budwell, Keith Speights, and Cory Renauer]

    So, to help investors separate the wheat from the chaff, we asked our Foolish contributors which stocks they thought are worth owning until at least 2030. These three healthcare specialists recommended Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), andIntuitive Surgical (NASDAQ:ISRG). Read on to find out why.

best stocks to buy today: Petroleo Brasileiro S.A.- Petrobras(PBR)

Advisors’ Opinion:

  • [By Money Morning News Team]

    Petroleo Brasileira SA Petrobras (NYSE ADR: PBR) is Brazil’s largest oil company and it’s our seventh best oil stock of 2016. Petrobras is an oil and natural gas exploration and production firm. It is also an operator of oil tankers, pipelines, and terminals in South America and globally.

  • [By Chris Lange]

    And Petroleo Brasileiro S.A. (NYSE: PBR), better known as Petrobras, is scheduled to release its most recent quarterly results Tuesday. The consensus estimates call for a net loss of $0.05 per share, as well as $18.05 million in revenue. Shares ended the weekat $8.91. The consensus price target is $11.22, and the 52-week range is $4.98 to $12.56.

  • [By Craig Jones]

    Alan Knuckman of Bulls-Eye Option said on Bloomberg Markets that he would buy Petroleo Brasileiro SA Petrobras (ADR)(NYSE: PBR), because it could benefit from the strength in crude oil.

best stocks to buy today: Citigroup Inc.(C)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Citigroup (C) has declined0.5% to$58.09 after its earnings topped the Street consensus but its sales fell shortof analyst expectations.

    United Continental Holdings (UAL) has dropped 1.7% to$72.50 despite beating earnings and revenue forecasts.

  • [By Matthew Cochrane]

    With this mindset, it is no wonder that PayPal finished 2016 on a wave of deal-making momentum. In the past 12 months, PayPal completed agreements with a number of financial and tech companies including Alibaba Group Holding Ltd (NYSE: BABA), Citigroup Inc (NYSE: C), Facebook Inc (NASDAQ: FB), Mastercard Inc (NYSE: MA), Visa Inc (NYSE: V), and Vodafone Group Plc (NASDAQ: VOD).

  • [By WWW.THESTREET.COM]

    Some money managers are indeed preparing for Armageddon, expecting a thin summer trading season to usher in the bear. But Cramer said that, ultimately, what happens in Washington has little impact on the earnings of stocks like Walmart (WMT) , Coca-Cola (KO) or Citigroup (C) . It also has no correlation to the 17.8% move in Nvidia (NVDA) , nor the 12.8% jump in Electronic Arts (EA) .

  • [By Elizabeth Balboa]

    It’s happened to AT&T Inc. (NYSE: T). It’s happened to Citigroup Inc (NYSE: C). It’s happened to Chevron Corporation (NYSE: CVX), General Motors Company (NYSE: GM) and Sears Holdings Corp (NASDAQ: SHLD)'s predecessor Sears, Roebuck & Co.

  • [By Craig Jones]

    Pete Najarian said on CNBC’s Fast Money Final Trade that Citigroup Inc (NYSE: C) is going to trade higher. He noticed unusually high call options buying in the name.

  • [By Stephen Mack]

    But here’s the thing: One of those banks, Citigroup Inc. (NYSE: C), just rose 14.3% in a four-week period, leaving Money Morning Options Trading Specialist Tom Gentile to wonder, “how much better can they do?”

best stocks to buy today: Westell Technologies, Inc.(WSTL)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested small cap high-performance wireless infrastructure solutions stock Westell Technologies (NASDAQ: WSTL) as a buy for our short-term portfolio:

best stocks to buy today: Exterran Corporation(EXTN)

Advisors’ Opinion:

  • [By Dustin Parrett]

    Company Name

    Share PriceYTDMarket CapClayton Williams Energy Inc. (NYSE: CWEI)$138.8216.4%2.4BDiamondback Energy Inc. (Nasdaq: FANG)$106.365.42%$9.38BWestern Gas Partners LP (NYSE: WES)$65.6411.71%$9.67BTesoro Logistics LP (NYSE: TLLP)$59.3416.79%$6.25BResolute Energy Corp. (NYSE: REN)$46.0811.87%$931.13MAntero Midstream Partners LP (NYSE: AM)$34.9813.28%$6.4BExterran Corp. (NYSE: EXTN)$33.9942.22%$1.19BDominion Midstream Partners LP (NYSE: DM)$32.9011.34%$2.6BNextEra Energy Partners LP (NYSE: NEP)$31.1922.12%$1.68BArchrock Inc. (NYSE: AROC)$16.0021.21%$1.12B

    While some of these stocks have performed well, we arent recommending this list of natural gas stocks. Thats because we arent interested in stocks that have already peaked at Money Morning; were interested in the next big winner. And we have one that could surge in 2017

Top 5 Safest Stocks To Buy Right Now

Chipotle (NYSE:CMG) is now one of the major focuses of activist investor Bill Ackman after Pershing Square dumped its Valeant Pharmaceuticals (NYSE:VRX) stake. Ackman showed he has the patience to wait out a turnaround, as exhibited with VRX.

However, Ackman is cleaning up his portfolio. He’s also positioned himself, per an SEC filing in March, to be able to sell his near 3 million stake from time to time without having to file multiple registration statements.

Yet, CMG has started to regain strength. The stock is up 25% in 2017. This could give Ackman the encouragement to ride this out. Pershing’s average cost is right around $415 a share.

Top 5 Safest Stocks To Buy Right Now: Netease.com Inc.(NTES)

Advisors’ Opinion:

  • [By Sreekanth Anasa]

    Shares of Hangzhou, China-based NetEase Inc (NASDAQ:NTES)popped 14% in the Feb 16th trading session after the company reported stellar Q4 and full-year 2016 earnings on Feb 15th after market close. The Chinese online gaming giant delivered an EPS of $4.30 on revenues of $1.74B beating EPS estimates by $0.86 and revenue estimates by $16oM. NetEase’s revenue grew by an impressive 53.1% YoY for Q4 and 67.7% for the full year 2016. On the back of these strong numbers, NTES stock closed at an all-time high of $298.73 in yesterday’s trading session. NTES stock might have gone up very high too soon. There could be a correction around the corner but still NTES stock is a great long-term proposition with much more upside left. Here’s why.

  • [By Joe Tenebruso]

    Shares ofNetEase (NASDAQ:NTES)popped 20.1% last month, according to data provided byS&P Global Market Intelligence, as the Chinese internet technology company’s strong fourth-quarter earnings report was applauded by investors.

Top 5 Safest Stocks To Buy Right Now: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
    Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today!   Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’d use today’s weakness to buy Merck (MRK) , Eli Lilly (LLY) , Pfizer (PFE) and Allergan (AGN) , an Action Alerts PLUS holding.

  • [By Chris Lange]

    Eli Lilly & Co. (NYSE: LLY) saw its shares in free fall on Wednesday, not from the usual rhetoric of politicians or even the election, for that matter, but a late-stage trial failure. As 24/7 Wall St. has said time and again, clinical trials can make or break biotech and pharma companies. In this case Eli Lilly hit new 52-week lows, not seen since 2014 and this will not be a loss that Eli Lilly will easily forget. Effectively, the company announced results from its Phase 3 solanezumab trial in people with mild dementia due to Alzheimers disease (AD).

  • [By Johanna Bennett]

    Eli Lilly & Co. (LLY) and Biogen (BIIB) are far from the only two drug makers racing to deliver a new treatment for Alzheimers disease. But they are pretty much leading the pack.

    The market for an effective therapy that actually slows the progression of the disease would likely generate billions of dollars in annual sales. It is quite literally the drug industrys version of the holy grail.

    And according to Barclays analysts Geoff Meacham and Paul Choi, the next few weeks could prove to be one of the most fertile periods in Alzheimers disease research since 2008.

    We think the most likely outcome for Lilly’s Phase 3 EXPEDITION 3 (E3) solanezumab trial is the primary cognition (ADAS-Cog14) endpoint is met (just achieving statistical significance with a p-value <0.05) and mixed results on the secondary endpoints including function (ADL), which we believe should be good enough to support a regulatory submission. While aducanumab has a marginally different mechanism of action, we nevertheless expect BIIB shares to trade in sympathy to Lilly.

    Implications for Biogen and Merck: The E3 results are likely to result in volatility for Biogen (up 20-30%, down 10-15%) as Alzheimer’s drives both long-term growth and M&A value even though aducanumab works differently from solanezumab.

    Aducanumab dose titration data is expected at the CTAD meeting (San Diego, Dec. 9). Merck’s Phase 2/3 EPOCH verubecestat (BACE) trial is scheduled to finish in June 2017 but unlike E3, PET scans/CSF tests for A were not an inclusion criteria. We think Merck shares could move 3% to 5% in either direction in sympathy to E3.

    At $76.58, Lillys share price has fallen more than 9% over the past year, while Biogen has climbed more than 9% over the same span.

  • [By David Zeiler]

    Pharma stocks shot up in the wake of Donald Trump’s victory. Eli Lilly and Co. (NYSE: LLY) and Merck & Co. (NYSE: MRK) both rose about 6%, while Pfizer Inc. (NYSE: PFE) jumped 7%.

Top 5 Safest Stocks To Buy Right Now: SCIENCE APPLICATIONS INTERNATIONAL CORPORATION(SAIC)

Advisors’ Opinion:

  • [By Monica Gerson]

    Wall Street expects Science Applications International Corp (NYSE: SAIC) to report its quarterly earnings at $0.74 per share on revenue of $1.15 billion. SAIC shares gained 0.96 percent to $57.87 in after-hours trading.

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

  • [By Monica Gerson]

    Science Applications International Corp (NYSE: SAIC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.15 billion.

Top 5 Safest Stocks To Buy Right Now: ChannelAdvisor Corporation(ECOM )

Advisors’ Opinion:

  • [By Lisa Levin]

    ChannelAdvisor Corp (NASDAQ: ECOM) shares dropped 24 percent to $10.85 following Q4 results. ChannelAdvisor reported Q4 net income of $5.8 million on revenue of $31.8 million.

Top 5 Safest Stocks To Buy Right Now: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Keith Fitz-Gerald]

    I’ve long thought that Medtronic (NYSE:MDT) would be a suitable buyer, as was the subject of unconfirmed rumors last month. However, I could also envision a defense contractor moving in simply because so much of the intellectual property could easily crossover to military applications. Or, even Google X for that matter.

  • [By George Budwell, Keith Speights, and Cory Renauer]

    So, to help investors separate the wheat from the chaff, we asked our Foolish contributors which stocks they thought are worth owning until at least 2030. These three healthcare specialists recommended Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), andIntuitive Surgical (NASDAQ:ISRG). Read on to find out why.

  • [By Todd Campbell]

    At Medtronic (NYSE:MDT), one of the country’s largest medical-device companies, these sensors are even attached to an insulin pump patients wear that canautomatically administer insulin as it’s needed.

  • [By ]

    Medical device makers will also be in the price-control crosshairs. If the government can mandate drug prices, the same can be expected for pacemakers, artificial joints and other devices. Companies such as Medtronic (NYSE: MDT) and previously mentioned pharma giant Johnson & Johnson will find themselves adjusting to a new paradigm.

preferred stock

Related JPM The Stocks That Moved The S&P, Dow And Nasdaq Yesterday JPMorgan Rockets Higher It's Not Only Campaigns That Are Going Negative (Seeking Alpha)

Dan Nathan recommended on CNBC’s “Options Action” a bearish options strategy in JPMorgan Chase & Co. (NYSE: JPM).

He said that JPMorgan Chase & Co. is the only bank that is trading significantly above its August lows, and he can’t understand why it is showing such a relative strength. Nathan believes that the banking sector could struggle after the stress test results and after the Q1 earnings so he wants to set up a position that can last until the April Expiration.

preferred stock: ImmunoCellular Therapeutics, Ltd.(IMUC)

Advisors’ Opinion:

  • [By Paul Ausick]

    ImmunoCellular Therapeutics Ltd. (NYSEMKT: IMUC) posted a new 52-week low of $0.48 on Tuesday, down nearly 61% compared with Monday’s closing price of $1.22. Volume totaled around 7.3 million shares, nearly 25 times the daily average. The company had no specific news Tuesday. The company price an offering of 5,000 preferred stock and warrants to purchase another 9,000 shares of preferred stock a $1,000 per share to raise approximately $5 million.

preferred stock: Smithfield Foods Inc.(SFD)

Advisors’ Opinion:

  • [By John Udovich]

    Thanksgiving is almost here but the exit of both Pilgrim’s Pride Corporation (NYSE: PPC) and Smithfield Foods (NYSE: SFD) to focus on their chicken or pork businesses (the latter was also acquired by the Chinese) leaves just two big Thanksgiving turkey stocks, Hormel Foods Corporation (NYSE: HRL) and Seaboard Corporation (NYSEAMEX: SEB), for investors to consider. According to the American Far Bureau, a 16-pound turkey will (on average) come in at a total of $22.74 this year or roughly $1.42 per pound for a decrease of 2 cents per pound or a total of 30 cents per whole turkey, compared to 2015. The price drop may be a transition back to the norm as the significant bird flu outbreak last year hurt the nations supply of both turkey and eggs.

preferred stock: The Blackstone Group L.P.(BX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Private equity giant Blackstone (BX) on Saturday announced that Saudi Arabia would invest $20 billion in a new $40 billion infrastructure fund for projects mainly in the United States. On Sunday, Boeing (BA) said it had signed several defense and commercial deals with Saudi Arabia. Trump was referenced in both deal announcements.

  • [By WWW.THESTREET.COM]

    SeaWorld Entertainment (SEAS) is probably the most famous example of a company that’s suffered from animal cruelty allegations. Shares of the theme park operator, backed by Blackstone (BX) , have never recovered from the release of the 2013 documentary Blackfish, which argued that orca captivity is inhumane and dangerous to the human trainers of the orcas. SeaWorld announced in March that it would phase out its orca captivity, breeding and live shows. The company’s remaining whales, most of which were born in captivity, will live out their lives at the parks. The news sent SeaWorld shares soaring 9%, but continued attendance drops forced the company to slash its dividend and invest $175 million in new attractions.

  • [By Matthew DiLallo]

    Sanchez Energy’s stock has continued to run higher in 2017 and is up nearly 50% since the start of the year. Fueling that surge is the announcement that the company found an exceptional place to put its liquidity to work. In mid-January, the company unveiled a strategic partnership with a private equity giant, Blackstone Group (NYSE:BX), to acquire Anadarko Petroleum’s (NYSE:APC) Eagle Ford shale assets for $2.3 billion. Under the terms of the deal, Sanchez and Blackstone entered a 50-50 partnership to own the Anadarko assets, which consist of 155,000 net acres that currently produce 67,000 BOE/D and hold more than 4,000 drilling locations that are economic at current prices. Sanchez will finance its share of the deal with cash on hand, a new bank lending arrangement, and a preferred equity issuance to Blackstone’s credit arm.

  • [By Money Morning Staff Reports]

    At least if private-equity leviathan Blackstone Group LP (NYSE: BX) CEO Tony James has anything to say about it.

    You see, James has a working theory about what to do with the U.S. retirement system that currently charges participants large 401(k) and 403(b) asset and consulting percentage fees…

  • [By Dan Caplinger]

    NCR’s first-quarter results were solid and continued the company’s positive momentum. Sales were up 2% to $1.48 billion, and while that was only a small gain, it was larger than the 1% rise that most investors were expecting. On a GAAP basis, NCR lost money during the quarter, but after excluding impacts from the company’s transaction with Blackstone Group (NYSE:BX), adjusted earnings of $0.56 per share were up by nearly half from year-ago levels and were stronger than the $0.46 per share consensus forecast among those following the stock.

preferred stock: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By Ben Levisohn]

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

  • [By Paul Ausick]

    Medtronic plc (NYSE: MDT) dropped about 2.6% Tuesday to post a new 52-week low of $69.35 after closing Friday at $71.23. The 52-week high is $89.27. Volume of around 8.6 million was about 20% more than the daily average of around 6.2 million shares traded. The company’s stock was downgraded this morning at Morgan Stanley.

  • [By Keith Fitz-Gerald]

    I’ve long thought that Medtronic (NYSE:MDT) would be a suitable buyer, as was the subject of unconfirmed rumors last month. However, I could also envision a defense contractor moving in simply because so much of the intellectual property could easily crossover to military applications. Or, even Google X for that matter.

  • [By ]

    Medical device makers will also be in the price-control crosshairs. If the government can mandate drug prices, the same can be expected for pacemakers, artificial joints and other devices. Companies such as Medtronic (NYSE: MDT) and previously mentioned pharma giant Johnson & Johnson will find themselves adjusting to a new paradigm.

  • [By Matthew Briar]

    What do you get when you combine a medical device company like Medtronic plc (NYSE:MDT) and a mobile communication device like the iPhone from Apple Inc. (NASDAQ:AAPL)? You get a CardioComm Solutions Inc. (OTCMKTS:EKGGF, CVE:EKG), which can turn your smartphone into a high-powered, high-functioning heart-monitoring piece of hardware as potent as anything you’d have access to in the hospital.

    Yes, there’s a market for the melding of what Apple and Medtronic — and several other players — do. The healthcare wearable market was worth $5.1 billion in 2015, and now that such technologies are being accepted, its revenues could reach $19 billion by 2020. Meanwhile, the heart-monitoring space happens to be a market worth more than $20 billion per year, and some say it will be worth $26.7 billion by 2020. CardioComm Solutions is nestled nicely between the two of them.

    CardioComm Solutions is the name behind a brand of wellness products sold under the HeartCheck monikor. Those devices are small, handheld portable ECG (electrocardiogram) readers that put the power of a doctor’s or hospital’s heart-monitoring hardware in the hands of individuals who can use them just as effectively.

    Its flagship products are the HeartCheck ECG Pen, for consumers (available without a prescription), and the HeartCheck ECG monitoring device (available only by prescription) that’s a higher-level technology. More are on the way too. The ECG ‘Card’ is a credit-card sized device that syncs up with — and is powered by — a smartphone in close proximity. Also on the way is the HeartCheck band, which is worn on the wrist. It does a lot that the Fitbit bands do, with the added benefit of being able to produce clinical-grade ECG readouts viewable not just by the user, but by a doctor, clinic, or call center if that user chooses to deliver them remotely using the company’s platform.

    Bolstering the value proposition is the fact that all of its wares are — or will be

Top 10 Bank Stocks To Own For 2018

The November election caught me be surprise. I find it hard to complain about the resulting appreciation in the S&P, but now that it has cooled, I, like other investors, just don’t know enough about Trump’s policies to make an educated investment decision. I was looking at banks, as the ever-present rate hike looms on the horizon into 2017, but I can’t shake the feeling of a financials pullback. Industrials had a great run, but with a rate hike and dismal global outlook, I can’t be sure about that, either. Oil and energy plays looked good as well, but with global demand and constant commodity volatility, that’s a tough call, too.

To look for some direction, I went over Trump’s Cabinet appointments, and the Education Secretary caught my eye. Betsy DeVos was appointed as Education Secretary, and I believe her staunchly conservative policy bodes well for a trade on government-funded student loans. These loans carry an average 11% default/delinquency rate, provide below average coupon payments, and carry a higher repayment risk than most debt securities. This is because students aren’t able to make large payments, and have more forebadance/deferment options than regular debtors. For these reasons, I believe the timing is right to short Navient (NASDAQ:NAVI).

Top 10 Bank Stocks To Own For 2018: Noble Energy Inc.(NBL)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Noble Energy (NBL) : “Noble’s good. It’s a very well-run, conservative company. It should do well in this environment.”

    Himax Technologies (HIMX) : “That area is so red-hot. I think it’s fine, but I like Cypress Semiconductor (CY) more.”

  • [By Paul Ausick]

    Noble Energy Inc. (NYSE: NBL) is rated a Buy and Jefferies raised the price target to $47. The 2017 net loss estimate was lowered from $0.40 per share to $0.22 per share. The 2018 EPS estimate was raised from $0.94 to $1.34. Shares closed at $36.71 on Friday, in a 52-week range of $28.82 to $42.03, and the consensus price target is $48.22.

  • [By WWW.THESTREET.COM]

    In his second “Executive Decision” segment, Cramer sat down with David Stover, chairman and CEO of Noble Energy (NBL) , the oil exploration and production company with acreage in all of the best regions of the U.S.

  • [By Ben Levisohn]

    Noble Energy (NBL) soared to the top of the S&P 500 today after purchasing Clayton Williams Energy (CWEI) for $2.7 billion.

    Agence France-Presse/Getty Images

    Noble Energygained 7.1% to $40.05, while the S&P 500 fell 0.3% to2,267.89.

    Wunderlich’s Irene Haas explains why she’s a fan of the deal:

    Noble Energy (NBL) has agreed to acquire Clayton Williams Energy Inc. (CWEI-$103.98, Hold) for $3.4 billion. The transaction has been approved by both boards and should close during 2Q17. NBL will gain 71,000 net acres in Reeves County, production of 10,000 boepd, and 2,400 gross locations (with 8,000 lateral length) in the Wolfcamp, with net un-risked resource potential of over 1 billion boe. Netting out production, acreage outside of Reeves County, and midstream assets, NBL valued the Reeves County acreage at~$32,000 per net acre. NBL has the balance sheet and the technical expertise to develop the project quickly and generate meaningful production and cash flow growth. We reiterate our Buy rating on NBL.

    Noble Energy’s market capitalization rose to $17.2 billion from $16.1 billion on Friday. It reported a net lossof $2.4 billion on sales of $3 billion in 2015.

Top 10 Bank Stocks To Own For 2018: EPR Properties(EPR)

Advisors’ Opinion:

  • [By Laurie Kulikowski]

    We rate EPR PROPERTIES as a Buy with a ratings score of B. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company’s strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, expanding profit margins and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. 

  • [By Laurie Kulikowski]

    The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Real Estate Investment Trusts (REITs) industry average. The net income increased by 17.5% when compared to the same quarter one year prior, going from $42.71 million to $50.20 million.

     

  • [By Laurie Kulikowski]

    EPR’s revenue growth has slightly outpaced the industry average of 6.1%. Since the same quarter one year prior, revenues slightly increased by 9.7%. This growth in revenue appears to have trickled down to the company’s bottom line, improving the earnings per share.

     

  • [By Laurie Kulikowski]

    EPR’s investment pipeline should drive about 6-7% earnings growth in 2016, and historically the company’s dividend growth has roughly equated to earnings growth. Starting with an above-average 6.5% yield, we find this compelling for income-oriented investors. 

  • [By Laurie Kulikowski]

    Net operating cash flow has increased to $64.42 million or 19.61% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 9.39%.

    The gross profit margin for EPR PROPERTIES is currently very high, coming in at 73.12%. Regardless of EPR’s high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, EPR’s net profit margin of 46.18% significantly outperformed against the industry.

     

Top 10 Bank Stocks To Own For 2018: Alexco Resource Corp(AXU)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Alexco Resource (NYSEMKT: AXU) operates in two segments: an environmental services business and a mining company. Its mining segment explores developments in Canada, while its environmental segment provides consulting and project management services in the United States and Canada. AXU is up over 400% YTD. The stock has been steadily rising since January. It isn’t clear what’s driving AXU upwards, other than general investor speculation. The stock is trading at $1.72 per share as of Monday intraday.

Top 10 Bank Stocks To Own For 2018: Arc Wireless Solutions Inc.(ARCW)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggested small cap manufacturing and 3D printing service provider ARC Group WorldWide (NASDAQ: ARCW) as a short trade:

Top 10 Bank Stocks To Own For 2018: McKesson Corporation(MCK)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    McKesson Corp. (NYSE: MCK), the leading pharmaceutical distributor, posted a revenue increase in the past year of $49.7 billion, up from $47.5 billion in ayear earlier. Its management offered hefty earnings for the quarter and year ahead. It continues to be a buyer of other companies, most recently Change Healthcare (which was labeled a merger with one of McKesson’s divisions). The current dividend is $1.12, or 0.61%.

  • [By Dan Caplinger]

    Drug-distribution specialist McKesson (NYSE:MCK) has had a tough year. Even as the overall stock market has climbed, the company’s shares have suffered, as investors fear that any business related to pharmaceuticals will have a political target on its back even under the current administration. Last quarter’s sluggish numbers didn’t create much enthusiasm for McKesson either.

  • [By Ben Levisohn]

    Clinton 15 stock basket (DBUSCLNT): UnitedHealth Group (UNH), Humana (HUM), McKesson (MCK), Aecom (ACM), Quanta Services (PWR), ExxonMobil (XOM), Alcoa (AA), NextEra Energy (NEE), Cree (CREE), First Solar (FSLR), Facebook (FB), Netflix (NFLX), Prudential Financial (PRU), Citigroup (C), Union Pacific (UNP).

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell by 1.77 percent. Meanwhile, top losers in the sector included McKesson Corporation (NYSE: MCK), down 24 percent, and Novo Nordisk A/S (ADR) (NYSE: NVO), down 13 percent.

Top 10 Bank Stocks To Own For 2018: WildHorse Resource Development Corporation (WRD)

Advisors’ Opinion:

  • [By Paul Ausick]

    WildHorse Resource Development Corp. (NYSE: WRD) raised $413 million on the sale of $27.5 million at $15 per share, well below the expected range of $19 to $21. Shares popped just 0.4% for the day and closed the week down 0.9%.

Top 10 Bank Stocks To Own For 2018: Telecom Argentina Stet – France Telecom S.A.(TEO)

Advisors’ Opinion:

  • [By Jim Robertson]

    Yesterday, our Under the Radar Moversportfolio newsletter suggested small cap telecommunications Telecom Argentina SA (NYSE: TEO) as a short/bearish trade:

  • [By Lisa Levin]

    Wednesday afternoon, the telecommunications services sector proved to be a source of strength for the market. Leading the sector was strength from Consolidated Communications Holdings Inc (NASDAQ: CNSL) and Telecom Argentina SA (ADR) (NYSE: TEO).

Top 10 Bank Stocks To Own For 2018: Fiat Chrysler Automobiles N.V.(FCAM)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    The showstopper by far in the early going is Waymo’s self-driving minivan (pictured below) in partnership with Fiat Chrysler (FCAM) . Waymo’s ultimate mom-mobile, coming from a business that was spun-off from Google’s parent company Alphabet Inc. (GOOG) last month, is equipped with self-driving sensors and vision systems.

Top 10 Bank Stocks To Own For 2018: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By Nelson Hem]

    Lawrence C. Strauss’s “Medtronic: Healthy and Getting Healthier” points out that some investors are skeptical about the prospects for this Dublin-based medical device maker. But are those investors underestimating the strength of Medtronic PLC (NYSE: MDT)? Find out why Barron’s believes the company’s shares could climb up to 15 percent over the next 12 months.

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Todd Campbell]

    At Medtronic (NYSE:MDT), one of the country’s largest medical-device companies, these sensors are even attached to an insulin pump patients wear that canautomatically administer insulin as it’s needed.

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Keith Fitz-Gerald]

    I’ve long thought that Medtronic (NYSE:MDT) would be a suitable buyer, as was the subject of unconfirmed rumors last month. However, I could also envision a defense contractor moving in simply because so much of the intellectual property could easily crossover to military applications. Or, even Google X for that matter.

  • [By Ben Levisohn]

    Cardinal Health (CAH) tumbled to the bottom of the S&P 500 today after agreeing to buy Medtronic’s (MDT) medical supplies business for $6.1 billion and offering disappointing guidance.

Top 10 Bank Stocks To Own For 2018: CBRE Group, Inc.(CBG)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of HAHN CAPITAL MANAGEMENT LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=HAHN+CAPITAL+MANAGEMENT+LLC

    These are the top 5 holdings of HAHN CAPITAL MANAGEMENT LLCHexcel Corp (HXL) – 899,271 shares, 4.71% of the total portfolio. Shares reduced by 1.47%Mohawk Industries Inc (MHK) – 212,515 shares, 4.68% of the total portfolio. Shares reduced by 2.38%CBRE Group Inc (CBG) – 1,299,059 shares, 4.34% of the total portfolio. Shares reduced by 2.39%Becton, Dickinson and Co (BDX) – 241,184 shares, 4.25% of the total portfolio. Shares reduced by 2.37%Ross Stores Inc (ROST) – 642,103

  • [By WWW.THESTREET.COM]

    In his second “Executive Decision” segment, Cramer also checked back in with Bob Sulentic, president and CEO of the real estate investment trust CBRE (CBG) , which has seen its stock rise 19% since Cramer last spoke with Sulentic just three months ago.

  • [By Lee Jackson]

    CBRE Group Inc. (NYSE: CBG) had a top hedge fund step in again last week and buy a huge block of shares. Value Act bought a total of 1,200,000 sharesat between $26.85 and $27.15. That cost the fund a gigantic $32 million.The companyoperates as a commercial real estate services and investment company worldwide, and its shares traded onFriday at $27.80.

  • [By WWW.THESTREET.COM]

    In his final “Executive Decision” segment, Cramer again welcomed Bob Sulentic, president and CEO of CBRE Group (CBG) , the real estate services company which reported a nine-cents-a-share earnings beat two weeks ago.